Enorama Pharma AB (publ) (STO:ERMA)
Sweden
· Delayed Price · Currency is SEK 0.280
0.00 (0.00%)
Apr 28, 2026, 5:09 PM CET
Enorama Pharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 2.74 | 15.77 | 1.36 | 6.85 | 12.8 | Upgrade
|
| Revenue Growth (YoY) | -82.63% | 1061.12% | -80.17% | -46.50% | 186.40% | Upgrade
|
| Cost of Revenue | 17.78 | 12.07 | 5.26 | 7.46 | 8.9 | Upgrade
|
| Gross Profit | -15.04 | 3.7 | -3.9 | -0.62 | 3.9 | Upgrade
|
| Selling, General & Admin | 46.61 | 31.13 | 34.39 | 37.83 | 29.99 | Upgrade
|
| Other Operating Expenses | 0.71 | -0.24 | -0.01 | -0.02 | -0.15 | Upgrade
|
| Operating Expenses | 47.78 | 51.3 | 37.92 | 41.35 | 31.23 | Upgrade
|
| Operating Income | -62.83 | -47.6 | -41.82 | -41.97 | -27.33 | Upgrade
|
| Interest Expense | -12.65 | -0.43 | -0.88 | -1.27 | -0.8 | Upgrade
|
| Interest & Investment Income | 0.32 | 0.14 | 0.08 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | 4.08 | -1.99 | 0.96 | 0.19 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.02 | - | - | - | 0.2 | Upgrade
|
| EBT Excluding Unusual Items | -75.14 | -43.81 | -44.61 | -42.28 | -27.74 | Upgrade
|
| Pretax Income | -75.14 | -43.81 | -44.61 | -42.03 | -27.74 | Upgrade
|
| Net Income | -75.14 | -43.81 | -44.61 | -42.03 | -27.74 | Upgrade
|
| Net Income to Common | -75.14 | -43.81 | -44.61 | -42.03 | -27.74 | Upgrade
|
| Shares Outstanding (Basic) | 69 | 53 | 28 | 8 | 6 | Upgrade
|
| Shares Outstanding (Diluted) | 69 | 53 | 28 | 8 | 6 | Upgrade
|
| Shares Change (YoY) | 30.99% | 91.50% | 253.96% | 26.23% | 11.44% | Upgrade
|
| EPS (Basic) | -1.08 | -0.83 | -1.61 | -5.37 | -4.48 | Upgrade
|
| EPS (Diluted) | -1.08 | -0.83 | -1.61 | -5.37 | -4.48 | Upgrade
|
| Free Cash Flow | -59.26 | -35.7 | -41.35 | -32.96 | -30.22 | Upgrade
|
| Free Cash Flow Per Share | -0.85 | -0.67 | -1.49 | -4.21 | -4.88 | Upgrade
|
| Gross Margin | - | 23.48% | -287.26% | -9.00% | 30.45% | Upgrade
|
| Operating Margin | -2293.79% | -301.87% | -3079.82% | -612.90% | -213.52% | Upgrade
|
| Profit Margin | -2743.30% | -277.82% | -3285.20% | -613.85% | -216.75% | Upgrade
|
| Free Cash Flow Margin | -2163.60% | -226.42% | -3044.85% | -481.35% | -236.14% | Upgrade
|
| EBITDA | -62.36 | -47.16 | -41.15 | -41.3 | -26.67 | Upgrade
|
| EBITDA Margin | - | -299.06% | - | - | -208.34% | Upgrade
|
| D&A For EBITDA | 0.47 | 0.44 | 0.68 | 0.67 | 0.66 | Upgrade
|
| EBIT | -62.83 | -47.6 | -41.82 | -41.97 | -27.33 | Upgrade
|
| EBIT Margin | - | - | - | - | -213.52% | Upgrade
|
| Revenue as Reported | -6.74 | 27.61 | 1.12 | 9.44 | 12.95 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.